Faculty of Medicine, University of Oslo, Oslo, Norway.
Acta Neurol Scand. 2012 Jul;126(1):23-31. doi: 10.1111/j.1600-0404.2011.01590.x. Epub 2011 Sep 8.
To assess the incidence of craniotomy for brain metastases, overall survival (OS), surgical mortality, and prognostic factors in a large, contemporary, consecutive series from a well-defined catchment area.
All patients ≥ 18 years who underwent craniotomies for intracranial metastases at Oslo University Hospital, Rikshospitalet and Ullevål, between 2005 and June 30, 2009 were included (n = 316). Patients were identified from our prospectively collected database and a thorough review of all charts to validate the entered data was performed.
The annual incidence of first-time craniotomy for a brain metastasis was 2.6/100,000 inhabitants. Patient age ranged from 25 to 87 years (median 64 years). The 30-day mortality rate was 3.8%. Median OS was 9.2 months. Recursive partitioning analysis was class I in 19.6%, class II in 59.2%, and class III in 21.2% with median OS of 16.2, 8.9, and 5.6 months, respectively (P < 0.001). Lung cancer and melanoma were associated with a higher risk (>1% per year) of developing brain metastases. Significant negative prognostic factors were age ≥ 65, a poor performance score, unstable extracranial disease, presence of extracranial metastases, multiplicity, metastasis in eloquent area, and no post-operative radiotherapy.
In this population study, the annual incidence of a first-time craniotomy for a brain metastasis was 2.6/100,000, the 30-day mortality rate was 3.8%, and median OS was 9.2 months. The well-known prognostic factors were confirmed.
在一个来自明确界定的集水区的大型、连续的系列中,评估开颅手术治疗脑转移瘤的发生率、总生存率(OS)、手术死亡率和预后因素。
纳入了 2005 年至 2009 年 6 月 30 日期间在奥斯陆大学医院、Rikshospitalet 和 Ullevål 接受颅内转移瘤开颅手术的年龄≥18 岁的所有患者(n=316)。通过我们前瞻性收集的数据库和对所有病历的详细审查来识别患者,以验证输入的数据。
首次开颅治疗脑转移瘤的年发病率为 2.6/100,000 居民。患者年龄为 25-87 岁(中位数为 64 岁)。30 天死亡率为 3.8%。中位 OS 为 9.2 个月。递归分区分析在 19.6%的患者中为 I 级,59.2%的患者为 II 级,21.2%的患者为 III 级,中位 OS 分别为 16.2、8.9 和 5.6 个月(P<0.001)。肺癌和黑色素瘤与脑转移瘤发生风险较高(每年超过 1%)相关。显著的负预后因素包括年龄≥65 岁、表现状态评分差、不稳定的颅外疾病、存在颅外转移、多发性、功能区转移和术后未行放疗。
在这项人群研究中,首次开颅治疗脑转移瘤的年发病率为 2.6/100,000,30 天死亡率为 3.8%,中位 OS 为 9.2 个月。证实了一些已知的预后因素。